Expert Guidance on the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer
Expert Guidance on the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer is organized by i3 Health.
Release Date: October 22, 2020
Expiration Date: October 21, 2021
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.5 hours of Category 1 credit for completing this program.
Nursing Continuing Professional Development:
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 0.5 contact hour may be earned by learners who successfully complete this continuing nursing education activity. This activity has been designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.5 contact hour.
Statement of Need:
An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as non-small cell. Most patients are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management (ACS, 2020). Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disease within 5 months of their final cycle (Lazzari et al, 2017). Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some patients. Unfortunately, the 5-year survival rate for patients with NSCLC remains a dismal 24%, indicating a need for continued research on more effective approaches to tumor control (ACS, 2020; NCI, 2019)
Upon completion of this activity, participants should be able to:
• Discuss how the potential for CNS disease and acquired resistance mutations can influence selection of first-line treatment for ALK-positive advanced NSCLC
• Evaluate the efficacy and safety of novel treatment sequences for ALK-positive advanced NSCLC
Mark G. Kris, MD (Chairperson)
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
Nathan Pennell, MD
Associate Professor of Medicine
Cleveland Clinic Taussig Cancer Center
- CME / CNE : 0.5
- MOC : 0.5
Social Media Info :
Toll free Number
Browse CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine